山楂中有效成分及其治疗非酒精性脂肪肝的作用机制研究进展OA
Research Progress on the Active Constituents of Cratargi Fructus and Their Mechanism of Action in Treating Nonalcoholic Fatty Liver Disease
目的:系统梳理山楂中主要有效成分及其治疗非酒精性脂肪肝的作用机制,为山楂治疗非酒精性脂肪肝病的临床应用、深入研究及开发利用提供参考.方法:本研究通过系统性文献回顾方法,以"山楂""非酒精性脂肪肝"等为关键词,对中国知网(CNKI)、Web of Science和PubMed等国内外数据库进行检索,对近年来山楂中有效成分及其治疗非酒精性脂肪肝作用机制的研究进展进行综述.结果和结论:山楂富含黄酮类、有机酸、三萜类、多糖类等有效成分,可以通过调控脂质代谢、抗氧化、抗炎、调节肠道菌群、抗纤维化等多种途径减少肝脏脂肪沉积,阻止脂质过氧化,减轻肝脏炎症损伤,防止肝纤维化.山楂多成分、多靶点、多途径调控的特点,在治疗非酒精性脂肪肝方面具有独特优势.
Objective:To systematically summarizes the primary active constituents in Cratargi Fructus and their mechanism of action in the treatment of non-alcoholic fatty liver disease(NAFLD),aiming to provide a reference for the clinical application,in-depth research,and development and utilization of Cratargi Fructus for the treatment of NAFLD.Methods:This study employed a systematic literature review method,utilizing keywords such as"Cratargi Fructus"and"nonalcoholic fatty liver disease",to conduct searches in domestic and international databases including CNKI,Web of Science,and PubMed.It comprehensively reviews the research progress on the active constituents of Cratargi Fructus and their mechanisms of action in treating NAFLD in recent years.Results and Conclusion:Cratargi Fructus is rich in active constituents such as flavonoids,organic acids,triterpenes,and polysaccharides.It can reduce hepatic fat deposi-tion,inhibit lipid peroxidation,alleviate hepatic inflammation injury,and prevent liver fibrosis through multiple pathways.These include regulating lipid metabolism,exerting antioxidant and anti-inflammatory effects,modulating the gut microbiota,and providing anti-fibrotic effects.The characteristic multi-component,multi-target,and multi-pathway regulatory profile of Cratargi Fructus demonstrates unique potential in the and treatment of NAFLD.
代琪;桂子雅;董兆威;叶俏波;罗霄;张良
成都市药品检验研究院,四川成都 610045成都中医药大学基础医学院,四川成都 611137成都中医药大学基础医学院,四川成都 611137成都中医药大学基础医学院,四川成都 611137成都市药品检验研究院,四川成都 610045成都市药品检验研究院,四川成都 610045
医药卫生
山楂有效成分非酒精性脂肪肝作用机制
Cratargi FructusActive constituentsNonalcoholic fatty liver disease(NAFLD)Mechanism of action
《中国药物评价》 2026 (1)
39-45,7
国家重点研发计划项目(2023YFC3504100)四川省药品监督管理局科技计划项目(2025005)成都市药品化妆品安全风险研究项目(2025FX04)
评论